As the UK seeks to forge a new relationship with the EU, Andreas Sætre Hanssen of Onsagers explains how another non-member, Norway, has managed its IP regime
The emergence of big domestic drug companies is reshaping Russia’s pharmaceutical patent landscape. Mikhail Khmara and Yana Lipatova of ARS-Patent explain how originator and generic companies can navigate the country’s changing IP rules
Technological changes to the way that plants are developed and grown pose challenges to the way that plant breeders’ rights are protected. Ylva Skoglösa and Isabel Cantallops Fiol of Valea outline the problems and offer potential solutions
Multinational companies and SMEs will need to think carefully about whether using the Unitary Patent and the UPC will save them money. Micaela Modiano and Alessandro Sanchini of Modiano outline the factors they need to take into account
The UK referendum result has created confusion over the future of the Unitary Patent and the Unified Patent Court. Marianne Schaffner of Dechert argues that EU member states must push ahead with the plan
